// App-Quantinova.ai

1472 : Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy

Researchers

Presenter

  • Michael Postow

Principal Investigators

  • Michael Farwell

  • Michael Gordon

  • David Hays

  • Jeffrey Wong

  • Sumanta Pal

  • Delphine Chen

  • Gary Ulaner

  • Jonathan McConathy

  • Michael Graham

  • Anthony Shields

  • Annick Van Den Abbeele

  • Marcus Butler

  • Jacob Thomas

  • Przemyslaw Twardowski

  • Jayant Narang

  • Aman Singh

  • Agnish Dey

  • Kevin Maresca

  • Edmund Keliher

  • Feng Liu

  • Guillaume Potdevin

  • Guenter Schmidt

  • Michael Ferris

  • William Le

  • Ian Wilson

  • Ron Korn

  • Neeta Pandit-Taskar

  • Kim Margolin

Medical Centers

  • Pfizer, Cambridge, MA, USA

  • HonorHealth, Scottsdale, AZ, USA

  • Imaging Endpoints, Scottsdale, AZ, USA

  • CARTI, Little Rock, AR, USA

  • Dana-Farber Cancer Institute, Boston, MA

  • Hoag Hospital, Newport, CA, USA

  • University of Pennsylvania, Philadelphia, PA

  • University of Washington, Seattle, WA

  • St. John’s Cancer Institute, Santa Monica, CA, USA

  • HOAG, Los Angeles, CA, USA

  • Princess Margaret Hospital, Toronto, ON, Canada

  • University of Alabama, Birmingham, AL

  • Imaginab, Bracknell, UK

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • University of Iowa, Iowa City, IA

  • Astrazeneca, Munich, Germany

  • Karmanos Cancer Institute, Detroit, MI

  • City of Hope, Duarte, CA

Locations

  • United States

  • United Kingdom

  • Germany

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 8A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

Phase

  • II

Study Id's

  • NCT03802123

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved